In some cases, treatments such as acetylcholinesterase inhibitors may be considered, particularly in patients with pathogenic variants in congenital myasthenia genes (CHRNA1, CHRND, DPAGT1, and GFPT1). This evidence concerns the gene CHRNA1 and congenital myasthenic syndrome.